Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...
This ranking has been superseded. For the latest WSJ/College Pulse Rankings, please click here. The WSJ/College Pulse 2024 Best Colleges in the U.S. ranking rates the top 400 universities in the ...
Hamas and other militant groups kidnapped 251 people from Israel during the October 7, 2023 terror attacks. The last 20 hostages who were still alive were released on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback